EGFR and lung adenocarcinoma: To evaluate the impact of PIK3CA mutations on EGFR TKI treatment responses, we focused on the 344 EGFR TKI-treated EGFR mutant lung adenocarcinoma patients with EGFR TKI-naïve tissue specimens (Fig. 1).